Evaxion Biotech is a publicly traded company trading on NASDAQ, led by CEO Helen Katrina Tayton-Martin.
No upcoming earnings scheduled for Evaxion Biotech
No earnings announcement scheduled
Past 12 earnings reports for Evaxion Biotech
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Mar 5, 2026 | Q4 2025 | -$0.02Est: -$0.19 | +89.5% | -Est: $2.5M | -100.0% | — |
| Nov 6, 2025 | Q3 2025 | $0.01Est: -$0.21 | +104.8% | $7.5MEst: $2.5M | +199.7% | — |
| Aug 14, 2025 | Q2 2025 | -$0.02Est: -$0.55 | +96.4% | $37.0K | — | — |
| May 27, 2025 | Q1 2025 | -$0.01Est: -$0.70 | +98.6% | -Est: $60.0K | -100.0% | — |
| Apr 1, 2025 | Q4 2024 | -$0.07Est: -$0.15 | +53.3% | $122.0KEst: $1.7M | -92.7% | — |
| Oct 31, 2024 | Q3 2024 | -$0.40Est: -$3.10 | +87.1% | $3.0MEst: $120.0K | +2414.2% | — |
| Aug 14, 2024 | Q2 2024 | -$1.20Est: -$3.90 | +69.2% | $154.0KEst: $30.0K | +413.3% | — |
| May 28, 2024 | Q1 2024 | $0.30Est: -$5.60 | +105.4% | $51.0KEst: $37.0K | +37.8% | — |
| Mar 27, 2024 | Q4 2023 | -$16.00Est: -$16.00 | 0.0% | $73.0K | — | — |
| Dec 19, 2023 | Q3 2023 | -$21.00Est: -$19.00 | -10.5% | - | — | — |
| Aug 17, 2023 | Q2 2023 | -$21.00Est: -$21.00 | 0.0% | - | — | — |
| May 31, 2023 | Q1 2023 | -$24.00Est: -$24.00 | 0.0% | - | — | — |
We use cookies for analytics. See our Privacy and Cookie Policy.